Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
第一作者:
Chris,Twelves
第一单位:
Leeds Institute of Cancer and Pathology and St James's Institute of Oncology, Leeds, UK. Electronic address: c.j.twelves@leeds.ac.uk.
作者:
主题词
日常生活活动(Activities of Daily Living);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);白蛋白类(Albumins);厌食(Anorexia);抗肿瘤药(Antineoplastic Agents);体象(Body Image);骨肿瘤(Bone Neoplasms);脑肿瘤(Brain Neoplasms);乳腺肿瘤(Breast Neoplasms);脱氧胞苷(Deoxycytidine);呼吸困难(Dyspnea);埃博霉素类(Epothilones);疲劳(Fatigue);女(雌)性(Female);呋喃类(Furans);健康状况(Health Status);人类(Humans);酮类(Ketones);肝肿瘤(Liver Neoplasms);肺肿瘤(Lung Neoplasms);中年人(Middle Aged);恶心(Nausea);紫杉酚(Paclitaxel);聚乙烯二醇类(Polyethylene Glycols);生活质量(Quality of Life);入睡和睡眠障碍(Sleep Initiation and Maintenance Disorders);紫杉烷类(Taxoids);长春碱(Vinblastine);呕吐(Vomiting)
DOI
10.1016/j.ejca.2017.02.011
PMID
28360015
发布时间
2022-12-07
- 浏览67
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文